Table 4.
Univariate analysis table
| Adverse pregnancy outcomes | Non-adverse pregnancy outcomes | OR (95% CI) | P | |
|---|---|---|---|---|
| Number of cases | 82 | 180 | ||
| Age (<35 years/≥35 years) | 58/24 | 136/44 | 0.782 (0.438-1.416) | 0.409 |
| Pre-pregnancy BMI (<24 kg/m2/≥24 kg/m2) | 53/29 | 106/74 | 1.276 (0.746-2.206) | 0.378 |
| Fasting blood sugar (mmol/L) | 5.53±1.07 | 4.94±0.94 | 1.805 (1.375-2.408) | <0.001 |
| Gestational age (weeks) | 33.67±2.62 | 34.62±2.18 | 0.844 (0.753-0.943) | 0.003 |
| History of miscarriage (yes/no) | 28/54 | 52/128 | 1.276 (0.725-2.224) | 0.392 |
| Number of fetuses (single/multiple) | 71/11 | 166/14 | 0.544 (0.236-1.282) | 0.155 |
| Number of deliveries (primiparous/multiparous) | 16/66 | 46/134 | 0.706 (0.364-1.318) | 0.287 |
| Family history of hypertension (yes/no) | 19/63 | 32/148 | 1.395 (0.726-2.627) | 0.308 |
| Family history of diabetes (yes/no) | 10/72 | 25/155 | 0.861 (0.377-1.839) | 0.709 |
| Family history of diabetes (yes/no) | 9/73 | 18/162 | 1.110 (0.456-2.530) | 0.810 |
| 24-hour urine protein (g) | 3.86±0.30 | 3.72±0.35 | 3.414 (1.566-7.711) | 0.002 |
| After treatment NO (μmol/L) | 64.38±7.50 | 67.97±6.78 | 0.931 (0.894-0.966) | <0.001 |
| After treatment ET-1 (ng/L) | 69.07±11.82 | 61.26±10.61 | 1.066 (1.040-1.095) | <0.001 |
| After treatment DBP (mmHg) | 95.52±7.67 | 90.48±7.85 | 1.087 (1.049-1.129) | <0.001 |
| After treatment SBP (mmHg) | 146.67±9.75 | 140.79±10.43 | 1.056 (1.029-1.085) | <0.001 |
| Treatment options (combination of labetalol/magnesium sulfate alone) | 32/50 | 106/74 | 0.447 (0.260-0.758) | 0.003 |
BMI: Body Mass index; NO: Nitric Oxide; ET-1: Endothelin-1; DBP: Diastolic Blood Pressure; SBP: Systolic Blood Pressure.